Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $314,169.52 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Michael Chi sold 7,259 shares of Hims & Hers Health stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $43.28, for a total value of $314,169.52. Following the completion of the transaction, the insider now owns 193,601 shares of the company’s stock, valued at approximately $8,379,051.28. This represents a 3.61 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Michael Chi also recently made the following trade(s):

• On Friday, January 24th, Michael Chi sold 17,304 shares of Hims & Hers Health stock. The stock was sold at an average price of $31.00, for a total value of $536,424.00.
• On Friday, January 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The stock was sold at an average price of $24.07, for a total value of $174,724.13.
• On Tuesday, December 24th, Michael Chi sold 17,303 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.97, for a total value of $483,964.91.
• On Thursday, December 19th, Michael Chi sold 7,500 shares of Hims & Hers Health stock. The stock was sold at an average price of $26.00, for a total value of $195,000.00.
• On Tuesday, December 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The stock was sold at an average price of $32.25, for a total value of $234,102.75.
• On Monday, December 2nd, Michael Chi sold 2,054 shares of Hims & Hers Health stock. The stock was sold at an average price of $33.56, for a total value of $68,932.24.

Hims & Hers Health Stock Down 2.7 %

Shares of NYSE:HIMS opened at $43.56 on Wednesday. The company has a market capitalization of $9.52 billion, a price-to-earnings ratio of 99.01 and a beta of 1.35. Hims & Hers Health, Inc. has a 52 week low of $9.14 and a 52 week high of $46.01. The firm has a 50 day moving average of $30.73 and a 200 day moving average of $23.58.

Hedge Funds Weigh In On Hims & Hers Health

A number of large investors have recently bought and sold shares of the business. SlateStone Wealth LLC raised its stake in Hims & Hers Health by 4.0% in the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock worth $257,000 after buying an additional 413 shares in the last quarter. Blume Capital Management Inc. grew its holdings in Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 600 shares during the last quarter. Quest Partners LLC grew its holdings in Hims & Hers Health by 22.6% in the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after purchasing an additional 807 shares during the last quarter. Harbour Investments Inc. grew its holdings in Hims & Hers Health by 18.8% in the fourth quarter. Harbour Investments Inc. now owns 5,269 shares of the company’s stock worth $127,000 after purchasing an additional 833 shares during the last quarter. Finally, Stonekeep Investments LLC grew its holdings in Hims & Hers Health by 5.5% in the fourth quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock worth $410,000 after purchasing an additional 882 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

HIMS has been the subject of several analyst reports. Needham & Company LLC raised their price objective on shares of Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday, January 6th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. BTIG Research initiated coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective for the company. Morgan Stanley initiated coverage on shares of Hims & Hers Health in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price objective for the company. Finally, Bank of America downgraded shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and decreased their price objective for the stock from $32.00 to $18.00 in a research note on Thursday, November 14th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $25.13.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.